Page 773 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

Index 757

Segmented neutrophils, 168, 173 Splenomegaly, 453 characteristics, 198
Seminal uid Sporogony, 153 development sites

analysis o Sporozoites, 152, 153, 153 primary lymphoid tissue, 189, 189
macroscopic examination, 603 Spur cell hemolytic anemia, 299 secondary lymphoid tissue, 189–190, 190–191
microscopic examination, 604 Staining maturation, 199, 203
principle, 602, 603t principles, 50–51 measuring, AIDS, 635–636

specimen collection, 602–603 procedure, 51 monoclonal antibodies, 199–200
anatomy and physiology, 602, 603, 603t Stains lymphocytes, 189, 189t, 191, 198, 200–201
Septic emboli, 507 acid phosphatase in leukocytes, 686 lymphopoiesis, 200–201
Seronegativity, 356 alkaline phosphatase in leukocytes, 686–687, anycytes, 592

Serum, 27, 531 687 arget cells, 148, 148–149
Serum protein electrophoresis, 157 alpha-naphthyl acetate esterase with uoride argeted sequencing, 664
Severe congenital neutropenia (SCN), 251–252, inhibition, 687–688, 688 ay-Sachs disease, 345–346
252t Naphthol as-D chloroacetate esterase, 688, 688 d test (see erminal deoxynucleotidyl trans er-

Sexual cycle, 153 Prussian blue staining method, 690 ase ( d ) test)
Sézary cells, 425, 425 siderocyte stain, 690 eardrop cells, 149, 149
Shi reticulocytes, 110 Sudan black B stain, 690, 690–691 elolysosomes, 63
Shwachman-Diamond syndrome, 252 Standard deviation (SD), 17 elomeres

Sickle cell disease (SCD), 314, 330–331 Standard precautions, 6, 584 measurement, 251
epidemiology, 316 Standards, 16 molecular mechanisms, 251
etiology, 315 OSHA, 3 stem and progenitor cells, 251
laboratory testing, 318, 318, 318b precautions, 3 elophase, 68, 68b

DNA analysis, 319 sa ety, 2–3 erminal deoxynucleotidyl trans erase ( d ) test,
hemoglobin electrophoresis, 319, 319 Statistics, 624 691
high-pressure liquid chromatography, 319 Stem cell transplantation, 404, 637 Talassemia, 314
newborns screening, 319–320 Stokes Shi , 621 demographics, 323

prenatal diagnosis, 319 Stomatocytes, 148, 148 etiology, 323
management Stress reticulocytes, 110 pathophysiology, 323
blood trans usion, 320 Substitution studies, 697 α-thalassemia, 326, 326, 327
bone marrow transplant, 321 Sucrose hemolysis test, 686 β-thalassemia

drug therapy, 320–321 Sudan black B stain, cytochemical staining laboratory ndings, 324, 324–325
hematopoietic stem cell, 321 method, 516, 516 newborn screening, 325
in ectious diseases, 320 Sul emoglobin, 129 prenatal diagnosis, 325
pharmaceutical therapy, 321 Sur ace antigens, 59 prevention, 326

prevention, 321 Synapsis, 70–71 treatment, 325–326
treatment, 320 Synovial uid α-T alassemia, 326, 326, 327
pathophysiology arthrocentesis, 605 Hb H disease, 326
children, 317t aspiration, 605 Hb H disease, 223, 231, 326, 326

sickling, 316 clinical applications, 608, 608t hemoglobin constant spring, 326
vasoocclusion, 316, 316–317, 317 joints, anatomy and physiology, 604, 605 β-T alassemia, 229–230, 324, 324–326
signs and symptoms laboratory assays Toracentesis, 593
adults, 317–318 gross examination, 605–606, 606b Trombin, 557

children, 317 microscopic examination, 606–608 Trombin time, 698
pain, 318 Sysmex, 626 Trombocyte, 218
pregnancy, 317 Systemic circulation, 495–496 Trombocythemia (see Trombocytopathy)
pulmonary complications, 318 Systemic lupus erythematosus (SLE), 366–367, 506 Trombocytopathy

stroke, 318 drug induced, 516
syndrome, 321t T HELLP syndrome, 518
β-thalassemia, 321–322, 322 -cell and NK-cell neoplasms hemolytic-uremic syndrome (HUS), 517–518
C disease, 322, 322, 322b adult -cell leukemia/lymphoma, 425, 426 hereditary, 516, 516t

cell trait, 323 Mycosis ungoides, 424, 424–425, 425 hereditary platelet adhesion and aggregation
Sickle cell mutation, 72 Sézary syndrome, 424–425, 425 disorders, 520, 520–522, 520b, 521t,
Sickle cells, 146, 148, 148 -cell large granular lymphocytic leukemia, 522t
Sideroblastic anemia, 258, 259, 268 425, 426 platelet dys unctions types, 516t

Sideroblasts, 127, 267–268 -cell prolymphocytic leukemias cardiopulmonary bypass and platelet unc-
Siderocyte stain, 690 clinical signs and symptoms, 423 tion, 518
Siderosome, 63 epidemiology, 423 clonal hematopoietic disorders, 518–519
Siderotic granules, 152, 152 genetic eatures and Epstein-Barr Virus, laboratory tests, 517t

Siemens Healthcare Diagnostics, 625 423, 424t miscellaneous disorders associated with
Signet ring cells, 594 immunohistological eatures, 423, 424t platelet dys unction, 519–520
Single nucleotide polymorphisms (SNPs), 72, 655, laboratory ndings, 423–424, 424 myeloproli erative syndromes, 519
655b prognosis and treatment, 424 paraprotein disorders, 518

Smears -cell growth actor, 201 uremia, 517
leukocyte dif erential count, 673–674 -cell large granular lymphocytic leukemia (LGL), platelet membrane receptors, 518
malaria, 683–685, 684, 684t 425, 426 Trombocytopenia, 496
pericardial uid, 601 -cell prolymphocytic leukemias ( -PLLs) destruction/utilization, disorders o

Smudge cells, 196, 196–197 clinical signs and symptoms, 423 bacterial sepsis, 510
Sodium citrate, 28 epidemiology, 423 drugs, 510
Solar purpura (senile purpura), 508, 508 genetic eatures and Epstein-Barr Virus, 423, immune thrombocytopenia, 510
Solid organ transplantation, 637 424t isoimmune neonatal thrombocytopenia, 510

Soluble trans errin receptor (s R), 264 immunohistological eatures, 423, 424t posttrans usion purpura, 510
Southern blot technique, 660–661, 662, 663 laboratory ndings, 423–424, 424 in pregnancy, 510
Speci c actor inhibitors, 537 prognosis and treatment, 424 disseminated intravascular coagucoagulation
Spherocytes, 148, 148 -cell receptor ( CR) gene rearrangement, 662 (DIC), 507

Spiculated erythrocytes, 148 cells heparin-induced thrombocytopenia (HI ),
Splenic B-cell marginal zone lymphoma, 658, 659 anatomical origin, 189 510–512, 511